Mankind Pharma Q2FY26 Revenue Up 20.8% YoY, EBITDA Margin at 25.0%
Mankind Pharma's Q2FY26 revenue rose 20.8% YoY to ₹3,697 crore, with a 25.0% EBITDA margin. Domestic revenue increased by 14.5%, while exports grew significantly by 82.6%. Earning concall on 06th November, 2025.
The results show good growth and profitability, but the decrease in diluted EPS tempers the overall impact.
The announcement highlights strong revenue growth and a healthy EBITDA margin, indicating positive financial performance.
* Mankind Pharma's revenue increased by 20.8% YoY to ₹3,697 crore in Q2 FY26. * Domestic revenue grew by 14.5% YoY to ₹3,184 crore, while exports surged by 82.6% YoY to ₹513 crore. * EBITDA margin stood at 25.0% for Q2 FY26. * Diluted EPS for Q2 FY26 was ₹12.4, a decrease of 24.2% YoY. * For H1 FY26, revenue from operations was ₹7,268 crore, up by 22.6% YoY. * Domestic revenue for H1 FY26 was ₹6,285 crore, up 16.6% YoY, and exports were ₹982 crore, up 81.9% YoY. * The company's consumer healthcare business saw a revenue decline of 3% YoY in Q2FY26 due to GST and monsoon disruptions. * Management Commentary: "Mankind’s revenue increased by 20.8% supported by outperformance in Chronic and BSV consolidation, partially impacted by GST disruption." * Earning Concall Details: Date 06th November, 2025, Time 06:00 pm – 07:00 pm IST.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.